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Mouse liver sinusoidal endothelium 
eliminates hiV-like Particles from 
Blood at a rate of 100 Million per 
Minute by a second-Order Kinetic 
Process
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We crafted human immunodeficiency virus (HIV)-like particles of diameter about 140 nm, 
which expressed two major HIV-1 proteins, namely, env and gag gene products, and 
used this reagent to simulate the rate of decay of HIV from the blood stream of BALB/c 
male mice. We found that most (~90%) of the particles were eliminated (cleared) from the 
blood by the liver sinusoidal endothelial cells (LSECs), the remainder from Kupffer cells; 
suggesting that LSECs are the major liver scavengers for HIV clearance from blood. 
Decay was rapid with kinetics suggesting second order with respect to particles, which 
infers dimerization of a putative receptor on LSEC. The number of HIV-like particles 
required for saturating the clearance mechanism was approximated. The capacity for 
elimination of blood-borne HIV-like particles by the sinusoid was 112 million particles 
per minute. Assuming that the sinusoid endothelial cells were about the size of glass- 
adherent macrophages, then elimination capacity was more than 540 particles per hour 
per endothelial cell.
Keywords: liver sinusoidal endothelial cell, Kupffer cell, pinocytosis, endocytosis, clearance
nOn-Technical sUMMarY
We have engineered a small particle that resembles a human immunodeficiency virus (HIV) in size 
and surface structure in order to learn how HIV travels in the blood circulation. We use the mouse 
as a model of the human. These particles, when infused into the blood stream, are removed from 
blood very rapidly, within minutes, mostly by a particular kind of cell that lines the blood vessels of 
the liver, a cell referred to as liver sinusoidal endothelial cell (LSEC) (ell-seck). The rate of removal 
from blood suggests complex details of the mechanism of removal. The capacity of LSEC to remove 
HIV-like particles is astonishingly high, namely, about 100 million HIV-like particles per minute. We 
can estimate that a single blood vessel-lining cell (LSEC) removes more than 500 particles per hour. 
Abbreviations: LSECs, liver sinusoidal endothelial cells; KC, Kupffer cells; DIC, differential interference contrast; IF, immuno-
fluorescence; RFI, relative fluorescence intensity; VLP, HIV-like particle.
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Our findings have yet to be integrated into the understanding of 
the natural course of an HIV infection.
inTrODUcTiOn
A readily apparent but poorly understood aspect of the innate 
immune response is the rapid and copious removal (or clear-
ance) and subsequent degradation of blood-borne virus by the 
endothelium of the liver sinusoids (LSEC). This capacity of LSEC 
to remove virus is far more robust than like clearance by Kupffer 
cells (KC), which instead appear responsible mostly for the 
removal of larger particles such as bacteria and autologous cel-
lular material (1). LSEC clear small particles other than virus in 
a similar manner, particles such as virus-like particles expressing 
polyoma virus proteins (2), small immune complexes made of 
ovalbumin and IgG antibody (3), lipopolysaccharide (4), and very 
likely other nanoparticles. The LSEC thus constitutes an outpost 
of the innate immune system with which cytokines have been 
associated only rarely (5). The rapid elimination of such particles 
has prompted the liver to be referred to in common parlance as 
the “garbage dump” of the body.
The molecular mechanism by which these small particles are 
cleared by LSEC is only beginning to be known: Fc receptors for 
IgG on LSEC are required, we have found, for the clearance from 
blood of small immune complexes (1, 3). Scavenger receptor B-1 
(SRB1) binds and likely facilitates the removal of hepatitis virus 
C (HVC) from circulation (6, 7). More mechanistic details are 
needed.
We now continue these studies by characterizing carefully 
the rate and extent of removal of a virus-surrogate, i.e., a non-
infectious HIV-like particle that expresses the translation prod-
ucts of the env and gag genes of HIV and thus has structural and 
antigenic characteristics suitable for recognition by the immune 
system, both innate and adaptive. This reagent will give us the 
opportunity later to study the effects of anti-HIV-1 antibody on 
virus or VLP removal by the LSEC (8).
resUlTs
We engineered a small particle the size of a virus (HIV-like par-
ticle) that consisted of a viral membrane derived from cultured 
HEK-293 cells and expressed features of HIV, namely, the HIV 
CXCR4 envelope protein (gp160) and the gag protein p24, but 
lacked nucleic acid and accessory proteins required for replica-
tion (M&M). We refer to the particle as an HIV-like particle. The 
diameter of the particles, measured by high-resolution analysis 
of Brownian diffusion, was ~140 ±  5  nm, mode ±  SE, n =  43 
(M&M). The concentration of suspensions of HIV-like particles 
we measured using a p24 ELISA.
To ascertain the rate of removal (or clearance) of HIV-like 
particles from the mouse circulation, we infused HIV-like parti-
cles intravenously and assessed their concentration in peripheral 
blood periodically over the course of 30  min (Figure  1). The 
decay curve was plotted in four ways. First, plotting simply using 
linear measurements for both the vertical axis showing concen-
tration of HIV-like particles in blood (mean ±  SD) versus the 
horizontal axis showing time in minutes, the decay curve showed 
two phases, a sharp drop followed by a lengthy near-plateau, with 
nearly all HIV-like particles (~97%) being cleared within 10 min. 
The second phase showed a plateau suggesting nil or negligible 
clearance. It represented only ~3% of the infused dose and thus 
was not included in further analysis (Figures 1D,E). As the SD of 
the first data point at 1 min was large, we additionally show decay 
curves of three mice that represent the SD splay (Figure  1B). 
Plotting the data in the conventional log-linear manner, the decay 
was curvilinear, not at all characteristic of the anticipated pseudo-
first order reaction, which would show a straight line relationship 
(Figure 1C). However, showing the data as log–log and inverse 
linear–linear plots, we see straight lines (Figures  1D,E) (see 
Discussion).
We found experimentally that the liver is the major organ 
clearing Cy3-HIV-like particles from blood (Figure 2): the organ 
distribution experiment showed that, in 10 min, the majority of 
total recovered Cy3-HIV-like particles was associated with liver 
(~80%), whereas less than 2% of the total recovered dose associ-
ated with spleen and kidney. The fraction of the dose of HIV-like 
particles that associates with blood shown in the bar graph is not 
statistical significantly different (p > 0.05) from the amount that 
we have estimated in the clearance curves using the unlabeled 
HIV-like particles (Figure 1). In addition, an experiment com-
paring the clearance of unlabeled HIV-like particles with that of 
the Cy3-HIV-like particles (data not shown) suggests that the 
clearance kinetics were not significantly different, assuring that 
the labeling of HIV-like particles with Cy3 did not change the 
clearance property of the particle. These data, indicating strongly 
that the liver is the major organ clearing circulating HIV-like 
particles, are in concert with several published studies showing 
liver to be the major site of removal of a variety of blood-borne 
viruses and virus-like particles, with minimal uptake occurring 
in the lung, spleen, and kidney (1, 2, 9–12).
Also, 3 min after the intravenous infusion of a dose, we deter-
mined the cellular localization within the liver of fluor-labeled 
HIV-like particles by examining 5  µm sections of mouse liver 
using immunofluorescence confocal microscopy, distinguishing 
LSEC with fluor-tagged anti-mannose receptor antibody, and KC 
with fluor-tagged anti-macrophage antibody. Visual microscopic 
inspection indicated that the HIV-like particles were situated on 
or in sinusoidal cells and were absent from the lumens of cross-
sectioned sinusoids. The particles were much more abundantly 
associated with LSEC than with KC (Figure 3A). We have earlier 
illustrated the validity of these markers (1, 3). Substantiating 
this disparity quantitatively by estimating pixel fluorescence 
numbers and intensity, we found that 88% of HIV-like particles 
associated with LSEC while 12% associated with KC (Figure 3B). 
HIV-like particles were not found associating with hepatocytes. 
Additionally, the HIV-like particles associated with KC appeared 
aggregated while virus-like particles associated with LSEC 
appeared as fine puncta.
To ask whether liver uptake of HIV-like particles is saturable, 
we observed in Figure  1 that nearly the entire dose (2 ×  1010 
HIV-like particles) was removed from blood in 10 min (~97%), 
which suggests that the clearance mechanism was not saturated. 
Further, increasing the dose to 4 × 1010 did not saturate the clear-
ance mechanism as, again, nearly the entire dose was cleared 
FigUre 1 | hiV-like particles are cleared rapidly from murine circulation. Approximately 2 × 1010 HIV-like particles were intravenously infused by tail vein. The 
concentration of particles remaining in blood of the suborbital plexus over time was estimated using a p24 ELISA. (a) Shows a plot of mean ± SD of the decay 
curves. The curve was drawn using asymmetric sigmoidal five parameters simulation to smooth the connection of data points. (B) Shows decay curves of three 
different mice illustrating the splay of the SD in (a); one high, one mid-level, and one low. (c) Shows a log–linear plot of the data illustrating no straight line. (D) Plots 
the data in log–log fashion to reveal a straight line of pseudo second order kinetics. (e) Shows a reciprocal plot of the same data, showing also a straight line. The 
30-min data points that did not fall on the straight line are not shown; they represent less than 3% of the dose. Each data point represents mean ± SD of 26 BALB/c 
wild-type mice.
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in 10  min. Re-evaluating a published study of ours showing 
decay curves of human recombinant adenovirus (rAd5) in 
mice, saturation was not achievable with an intravenous dose of 
1.6 × 1011 rAd5 particles (1). Specifically, plotting vertically on 
a log scale three doses of rAd5 over a 2-log range versus, on the 
horizontal axis, the number of rAd5 removed in 10 min showed 
a straight line with a positive slope, indicating that the uptake 
mechanism was not saturated [curve not shown; data presented 
in Figure 1A of our paper (1)]. For technical reasons, we were 
unable to achieve higher doses of HIV-like particles; thus, with 
our present strategy failing to show saturation of the uptake 
mechanism, we can only assume that we are near saturation. For 
practical purposes, we assume, then, that a saturation dose is 
near 2 × 1010.
Proceeding, we reasoned that the removal from circulation of 
a large dose of HIV-like particle (2 × 1010) would leave the liver 
unable to remove a second dose as efficiently as the first; i.e., the 
liver may require time to recover its native removal ability. To cal-
culate this refractory period that follows a first dose, we infused 
a second dose at varying times (1.5–12 h) after the first dose and 
plotted decay curves of the second dose, comparing the two decay 
curves performed simultaneously, the second with the first. As 
measures of differences both in the extent and rate of decay, we 
compared the numbers of HIV-like particle cleared at every point 
on the two curves, experimental, and control (Figure 4).
The decay curves performed 12 and 6 h after a first dose were 
fully superimposable on the initial control decay curves and were 
not statistically significantly different from the control decay 
FigUre 2 | The liver is the major organ clearing cy3-hiV-like particles 
from blood. Mice were infused with 1010 Cy3-human immunodeficiency 
virus-like particles and, after 10 min of infusion, the Cy3 fluorescence was 
quantified in various organs as described in M&M. The bar graph expresses 
the percentage means and SDs of total Cy3 fluorescence that was recovered 
from the six organs studied. The asterisk represents data points where the 
p-Values were determined to be less than 0.05 using Student’s t-test.
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curves (Figures 4A,B). The decay curve at 3 h after the initial 
dose appeared to show disparity of later points, but the experi-
mental and control points throughout the entire curves were not 
statistically significantly different (Figure 4C). However, at 1.5 h 
after the initial dose, the decay curve plateaued earlier than the 
control curve (Figure 4D); the two curves were statistically and 
significantly different at the 5 and 10 min points (asterisks).
DiscUssiOn
The HIV-like particle used in this study was crafted to express 
multiple copies of two major HIV gene products, the surface-
expressed gp160 env protein for eventual use as an antibody 
target, and the gag protein p24 for use with an immunoassay.
We have learned from these data that the rate and extent of 
removal of blood-borne HIV-like particle in the mouse shows 
a biphasic decay curve with a very rapid and extensive first 
phase and a negligible second phase. Thus, decay is similar to 
the removal of blood-borne virus as studied by us and others 
[see our paper (1) for brief review]. However, we perceive a 
distinct difference from the decay of Ad5. By analogy with 
standard chemical reactions, the straight lines of the graphs of 
Figures  1D,E are characteristic of pseudo-second order reac-
tions with respect to HIV-like particle concentrations, assum-
ing a constant concentration of the sinusoidal binding site for 
HIV-like particles. In standard chemical parlance, the reaction is 
represented as 2A + B → AAB. In contrast, adenovirus clearance 
using data from an earlier study plotted in log-linear fashion 
showed a straight line characteristic of a pseudo first order reac-
tion (1).
We can only speculate what the apparent second order of 
VLP decay might mean. At face value, the data would suggest 
that two HIV-like particles are interacting as a unit with an 
LSEC target. We know of no reason why HIV-like particles 
should dimerize, and in fact, according to our Brownian motion 
detector, the HIV-like particles were monodisperse. Whether 
they dimerize in blood, we have no way of determining. It is 
also possible that the binding site on LSEC is a dimer, although 
we know of no evidence that CD4 or L-SIGN, both known to 
be expressed on LSEC (13, 14), dimerize. However, there is 
precedence for LSEC to express dimeric receptors; i.e., SRB-1, 
a receptor for HDL and HCV envelope protein E2 expressed 
on LSEC (6, 7, 15), is known to dimerize and oligomerize (16). 
What precisely second order means in the case of our Figure 1 
data awaits additional study.
We attempted to saturate the clearance mechanism of LSEC 
but were not at all successful. Doses of HIV-like particles as 
high as practicable, 4 ×  1010, were cleared nearly completely 
(97%) in 10 min, indicating that saturation had not yet been 
reached. Nor did we reach a saturating dose in our prior stud-
ies of human adenovirus clearance where doses equally high, 
1.6 ×  1011, were infused (1). For technical reasons, we were 
unable to study higher doses; thus, we assume that saturation 
is 2 × 1010.
Failing to find a saturating dose, we nevertheless were able to 
estimate a recovery time by examining closely the shape of the 
decay curves after a second dose of HIV-like particles. The decay 
curve of a second dose 1.5 h after the first was clearly different 
from the control, indicating, albeit tenuously, that the clearance 
mechanism was still recovering at 1.5 h. At 3 h, moreover, the 
decay curve looked abnormal in that it diverged from the control 
curve, but statistically it was no different than the control curve. 
By 6  h, however, the clearance mechanism had returned to 
superimposable on the normal curve and remained superimpos-
able at 12 h. We have not calculated half-lives because half-life 
is a function of dose in second order reactions; we did not vary 
the dose substantially. For practical purposes, we arbitrarily let 
recovery time be 3 h.
Assuming that the greatest dose used in our experiments 
(2 × 1010) is close to the saturation dose (S), and that the recov-
ery time (R) is 3 h, we can then calculate the capacity (C) of 
the liver to remove HIV-like particles from circulation in an 
on-going, continuous fashion. We define capacity in units of 
particles per day as the saturation dose divided by the recovery 
time R (C = S/R). Specifically, every 3 h, 2 × 1010 HIV-like parti-
cles were removed from circulation. The capacity for clearance, 
therefore, is 6.7 × 109 (2 × 1010/3) HIV-like particles per hour 
per mouse.
Is this a biologically realistic number? Capacity expressed as 
functions of hourly or daily clearance are numbers too large for 
us to conceptualize. However, converting to clearance per minute 
gives an everyday number that most workers will appreciate; i.e., 
112 million HIV-like particles per minute (6.7 ×  109/60  min). 
This number sounds realistic and substantial. In fact, the number 
sounds remarkably potent when compared to a lethal dose of an 
arbitrarily chosen widely known virus (influenza virus) which, 
given intratracheally, has been shown to be on the order of 104 
FigUre 3 | The majority of human immunodeficiency virus (hiV)-like particles cleared by liver is localized to the liver sinusoidal endothelial cell 
(lsec). (a) Four-color fluorescence microscopic images of 5 µm liver sections, 3 min after intravenous infusion of 2 × 1010 Cy3-HIV-like particles. (a) Red puncta 
show Cy3-HIV-like particles. (b) rabbit anti-mannose receptor (CD206) labeling of LSEC shown in green. (c) rat mab F4/80 labeling of KC shown in magenta. (d) 
Cy3-VLP (red) merged with LSEC marker. (e) Cy3-HIV-like particles (red) merged with KC marker. (f) Merged image showing Cy3-HIV-like particles (red), LSEC 
marker (green), and KC marker (magenta) plus DIC and DAPI staining of the nuclei (blue). Panels shown are representative of 160 images from three different mice. 
The scale bar in panel (c) signifies 5 µm. (B) Quantified association of HIV-like particles with cells of the liver. All HIV-like particles in the liver were associated with 
either LSEC or KC, indicating no association with hepatocytes. The total HIV-like particles was calculated as the pixel area × mean fluorescence intensity (red). 
HIV-like particles associated with the KC was subtracted from the total HIV-like particle to calculate LSEC association of HIV-like particle. The graph represents the 
mean ± SD of KC- and LSEC-association within liver. One hundred sixty images, roughly 50 from each of the three mice, were examined. The area totaled 30 mm2 
of sectioned liver tissue.
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virus particles (personal communication, Ian Davis, The Ohio 
State University).
Can we put the clearance capacity into perspective by ask-
ing how large is the sinusoid area responsible for clearing 112 
million particles/min? Calculating from the rat sinusoid area 
(17), assuming that mouse liver weight is 1 g, we find that the 
surface area of the mouse sinusoidal network is 5.8 × 1010 μm2, 
or roughly half the area of the face of a tennis racquet.1 Another 
way of rendering realistic the magnitude of the sinusoidal surface 
area is by thinking of it as covered by confluent adherent mac-
rophages. Assuming that the area of an adherent macrophage 
1 http://officialtennisrules.com/official-dimensions-for-tennis-rackets/.
FigUre 4 | clearance capacity of human immunodeficiency virus 
(hiV)-like particles is fully recovered in about 3 h. Mice were infused 
intravenously with 2 × 1010 HIV-like particles, allowed to recover for the 
indicated time (1.5, 3, 6, and 12 h) and then were infused with an additional 
bolus of 2 × 1010 HIV-like particles. The blood concentration of HIV-like 
particles was determined as described in Figure 1; the (sample) curves are 
to be compared with decay curves performed simultaneously on mice that 
had not received the initial dose of HIV-like particles (control). Each data point 
represents mean ± SD of several BALB/c wild-type mice. The number of 
animals used at each time period 1.5, 3, 6, and 12 h was 6, 3, 3, and 4, 
respectively. The raw data were log10-transformed prior to running the 
random-effects linear regression model, described in M&M. The 
corresponding points on the two curves in panels (12, 6, and 3 h) were not 
statistically different, even the apparently divergent points at 3 h. However, 
the corresponding points on the curves in panel (1.5 h) were statistically 
significantly different at the 5 and 10 min points, but not at the others. Thus, 
the recovery time was estimated to be between 1.5 and 3 h.
6
Mates et al. Liver Endothelium Eliminates HIV
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 35
is 4.5 × 103 μm2 (Figure 5 of publication PMC3488130), then 
the mouse sinusoid would be covered by 13 million confluent 
glass-adherent macrophages. Assuming further that the area 
of the adherent macrophage is about the same as a sinusoidal 
endothelial cell, then we find that 540 HIV-like particles are 
cleared per LSEC per hour (calculations in Supplementary 
Material).
What is the fate of the HIV-like particles once cleared from 
blood and bound to the LSEC? We interpret our data to indicate 
that HIV-like particles, cleared from blood, associate mostly 
(88%) with LSEC, to a small extent with KC (12%), and not at all 
with hepatocytes. At 3 min after infusion (Figure 3), they appear 
on or within the endothelium but not luminal as evidenced by 
their absence in luminal cross-sections. At 10 min after infusion, 
we find virtually no HIV-like particles associating with LSEC or 
KC (data not shown). We presume, based on the fate of immune 
complexes (18, 19), that most bound particles are internalized and 
degraded, although we have not yet embarked on a formal study 
of HIV-like particles. The literature indicates that endocytosed 
particles of many sorts are degraded (2, 11); other studies suggest 
that a fraction of the endocytosed particles is degraded and a 
fraction is expressed back onto the surface of the endocytosing 
cell (18, 20). The general impression that endocytosed particles 
are disposed of quickly is consistent with the novelty of our sug-
gestion; virus particles internalized by LSEC are not ordinarily 
described during the course of virus infections. In our recent 
study of LPS clearance from blood, we found no evidence that 
cleared LPS moved from LSEC to KC (4). A systematic study of 
the fate of cleared particles is needed.
A remarkable implication of this robust clearance capacity 
is that clearance may be fast enough to avoid detection in the 
blood by culture or nucleic acid assay while allowing hematog-
enous spread of infection. It would follow that blood cultures 
and nucleic acid assays would not become positive until the 
clearance capacity of the liver is saturated. These implications 
are testable.
Further, we would propose that two different viruses may com-
pete for a single clearance mechanism, although to date no such 
evidence is available. Such studies will require a keener analysis of 
the clearance mechanism and its discrimination among various 
bound particles. In support of this speculation, it has been known 
for decades that small particles in blood such as thorotrast will 
block the LSEC uptake of virus (10).
Finally, this astonishingly rapid and robust removal of 
blood-borne virus would appear to have been overlooked by all 
but a few modern and early biologists studying virus turnover 
during infection (10–12, 21). To us, this mechanism appears to 
be a subdivision of the innate immune system that has received 
little attention but might very well be of immense value to the 
organism. Many additional consequences of our observation, we 
anticipate, will become clear with appropriate study.
As a postscript, we point out that the rapidity of particle 
clearance described herein is remarkably similar to the classical 
“distribution” phase of the decay curves of protein and drug 
clearance from blood, a phenomenon well described in the phar-
macokinetics literature.2 However, beyond rapidity, the similarity 
stops. Virus leaving the plasma compartment bound to the LSEC 
surface does not appear to be in equilibrium with the plasma 
compartment, which by definition it must be if the rapid portion 
of decay is to be considered “distribution” of kinetic decay. We 
imagine that the rapidity seen in our studies is simply quick clear-
ance on a pathway toward ultimate degradation or processing by 
the sinusoidal cells.
MaTerials anD MeThODs
animals
Wild-type male BALB/c mice of age 10–15 weeks were obtained 
from Taconic Biosciences. All studies were performed in accord-
ance with appropriate guidelines and were approved by The Ohio 
State University Institutional Animal Care and Use Committee. 
All in vivo mouse procedures were performed under Isoflurane 
anesthesia.
2 http://sepia.unil.ch/pharmacology/?id=93.
7Mates et al. Liver Endothelium Eliminates HIV
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 35
Plasmids
The pGag-EGFP plasmid (NIHARP cat #11468) used to pre-
pare HIV-1 VLP, which directs Rev-independent expression 
of HIV-1 Gag-EGFP fusion protein (tier 1 clade B) to form 
VLP, was obtained from Dr. Marilyn Resh through the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH. The 
pGag-EGFP plasmid was constructed by cloning Gag from 
pCMV55M1-10 (22) into the pEGFP-N1 plasmid (Clontech) 
(23). Plasmid DNA was amplified in Escherichia coli DH5α; 
DH5α-containing pGag plasmid was grown in LB medium 
supplemented with 25 µg/mL kanamycin. The pHXB2 envelope 
plasmid (NIHARP cat#1069), containing HXB2 gp160 under an 
SV40 promoter, was obtained from Dr. Kathleen Page and Dr. 
Dan Littman through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH. Plasmid DNA was amplified in E. coli 
DH5α; DH5α-containing pHXB2 env plasmid was grown in LB 
medium supplemented with 50 µg/mL ampicillin. Plasmid puri-
fication used the BenchPro 2100 Plasmid Purification System 
(Invitrogen).
Preparation of VlP-containing hXB2 env
VLP were propagated using human embryonic kidney, 293T cells 
(ATCC). Cells were maintained in Dulbecco’s Modified Eagle 
medium with 10% Fetal Bovine Serum. VLP-containing HXB2 
envelope was produced by transient transfection of HEK 293T 
cells with pGag-EGFP and pHXB2 env using Lipofectamine 
2000 transfection reagent (Life Technologies). Also, 107 cells in 
T175 flasks were transfected with 30 µg HXB2 envelope, 60 µg 
pGag-EGFP, and 360 µL Lipofectamine 2000 transfection reagent 
in serum/antibiotic-free medium. After 3–4  h of incubation at 
37°C, the culture medium was replaced with DMEM + 10% FBS. 
VLP-containing supernatant was collected 72 h after transfection 
and clarified by centrifugation at 2,000 × g for 10 min. Clarified 
supernatant was further purified of cellular debris by 0.45  µm 
filtration. Purification of assembled VLP was completed by ultra-
centrifugation through a 20% sucrose pad at 122,000 × g for 2 h 
at 4°C. The VLP pellet was resuspended in filtered PBS.
Quantification of VlP
Two methods were used to quantify VLP concentrations, p24 
ELISA and Nanoparticle Tracking Analysis (NTA). p24, a viral 
protein component Gag, was used to determine VLP concentra-
tion with the commercially available Zeptometrix p24 ELISA kit 
in accordance with the manufacturer’s instructions. The lower 
limit of detectability in the assay was 107–2 × 107 particles/mL. 
Additionally, NTA was performed using a Nanosight NS300 
(Malvern). VLP samples resuspended in filtered PBS were diluted 
to approximately 108–109  particles/mL; 1  mL of diluted VLP 
sample was injected into the Nanosight apparatus. Nanosight 
NTA 3.0 software was used to analyze nanoparticle tracking 
data. Five individual videos ranging from 30 to 60 s each were 
recorded and analyzed based on the VLP Brownian motion at 
room temperature. NTA analysis determined both particle size 
and concentration of VLP per milliliter. A ratio of p24 concentra-
tion (picograms per milliliter) to NTA (VLP per milliliter) was 
calculated for each VLP preparation.
cy3 labeling of VlP
VLP in PBS, pH 7.4, at a concentration of 1012  VLP/mL was 
adjusted to pH 9.4 by the addition of 0.5 M sodium carbonate 
bicarbonate. The Cy3 monoreactive dye pack (Amersham) was 
dissolved in 1 mL of VLP solution, pH 9.4, and incubated at room 
temperature for 30 min with constant stirring. The addition of 
0.2% glycine stopped the labeling reaction, and the Cy3-labeled 
VLP was dialyzed against two changes of PBS, pH 7.4, at 4°C for 
18 h. The efficiency of Cy3-conjugation was assessed by compar-
ing the protein concentration (micrograms per microliter) of 
the dialyzed Cy3-conjugated VLP with the concentration of Cy3 
(picomoles per microliter). The Cy3 concentration was converted 
to micrograms per microliter using the formula weight; the dye to 
protein ratio of Cy3-conjugated VLP was 0.02.
immunofluorescence
BALB/c mice 11–14 weeks old were intravenously infused with 
2 ×  1010 Cy3-labeled VLP in PBS, pH 7.4. BALB/c livers were 
excised, cut into ~5 mm pieces, and fixed in 4% paraformalde-
hyde-PBS for 2 h at room temperature. Fixed tissue was washed 
with PBS and saturated with 20% sucrose-PBS overnight at 4°C. 
Upon sucrose saturation, tissue was embedded in tissue-freezing 
medium and stored at −80°C. Fixed and frozen tissue was sec-
tioned at 5 µm thickness by Cyrostat sectioning and collected on 
Superfrost microscope slides. Tissue sections were rehydrated, 
blocked in 5% milk blocking solution for 1 h, and then incubated 
with primary antibodies in 5% blocking solution overnight at 4°C. 
Unconjugated primary antibodies were visualized using a 1:200 
dilution of fluor-tagged secondary antibodies in 5% blocking 
buffer for 1 h at room temperature. DAPI staining was executed 
for 10 min and then tissue sections were mounted under cover-
slips with Prolong Gold Solution (Invitrogen). Isotype controls 
along with secondary antibodies were used to assess primary and 
secondary immunostaining.
Primary antibodies included rabbit polyclonal IgG anti-
CD206 mannose receptor (Santa Cruz) and rat monoclonal IgG 
anti-F4/80 (Abserotec). Secondary antibodies from Invitrogen 
included Alexa 488-conjugated goat anti rabbit IgG and Alexa 
680-conjugated goat-anti rat IgG.
Images were acquired using 405, 488, Cy3, and 680 laser set-
tings on an Olympus Fluo View 1000 Laser Scanning Confocal 
microscope with a spectral detection system designed for finer 
separation of fluorochromes (FV 1000 Spectral).
Quantification of hiV-like Particles  
in Various Organs
Approximately 1010 Cy3-labeled HIV-like particles were infused 
via the retro–orbital plexus of anesthetized mice and were sacri-
ficed at 10 min. The mice were bled of ~20 μL via the retro–orbital 
plexus, and organs (liver, kidney, lung, spleen, and heart) were 
removed and weighed. The weighed portions of the organs were 
homogenized and lysed with organ lysis buffer (0.1% SDS, 10 mM 
Tris, pH 7.4, and 1 mM EDTA) (3). The Cy3 fluorescence in organ 
lysates and blood was measured using fluorimeter (2300 Enspire 
multimode reader). The amount of Cy3 fluorescence associated 
with each organ was estimated by factoring the total organ weight 
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and after subtracting both the blood volume of that particular 
organ (24) and the background organ fluorescence from un-
infused age matched mice.
Quantification of the association  
of cy3-labeled VlP with liver cells
Based on 4-color immunofluorescence analysis of liver sections, we 
determined that Cy3-labeled VLP associated with LSEC and KC, 
but not hepatocytes or large vessel endothelium. The association 
of VLP with LSEC and KC was quantified with Image J software 
as described previously in our work (1). Briefly, quantification 
was determined in a three-step process: (1) image threshold was 
adjusted to account for background intensity not associated with 
Cy3 VLP, and the total Cy3 fluorescence intensity was recorded 
for the image; (2) each Kupffer cell (KC) within the image, identi-
fied by anti-F4/80 staining, was partitioned, and the fluorescence 
intensity of Cy3 associated with individual KC was recorded; the 
VLP intensity associated with individual KC was summed to total 
KC-associated VLP; and (3) the total KC-associated VLP intensity 
was subtracted from the total VLP intensity of the entire image 
to give the total LSEC-associated VLP intensity. KC and LSEC 
association was averaged for a total of 160 technical replicates of 
the images over the three mice. Within each mouse, the technical 
replicates were averaged producing three KC and three LSEC 
associations. The mean and SD of the three KC- and the three 
LSEC-association observations are presented and no statistical 
testing was done since these observations are not independent 
of each other.
clearance of VlP from the Bloodstream
Clearance is defined as elimination from blood. BALB/c male 
mice at age 14 weeks were infused intravenously via tail vein with 
2 × 1010 VLP in PBS, pH 7.4. After infusion, 20 µL of blood was 
obtained via the retro–orbital plexus at 1, 5, 10, 20 (or 15), and 
30 min using heparinized capillary tubes. The calculation of VLP 
concentration at the time of infusion (time 0) was based on the 
mouse weight and assumed total blood volume of ~2.58 mL/25 g 
mouse (25). Blood obtained at each time point was diluted 
and VLP were quantified using p24 ELISA (Zeptometrix) 
per the manufacturer’s instructions. The concentrations of p24 
in picograms per milliliter were converted to VLP per mil-
liliter using the calculated conversion rate between pictograms 
per milliliter and NTA. Clearance kinetics were plotted as 
concentrations of VLP per milliliter of blood versus time. The 
curve was biphasic with a fast phase, an inflection at about 
10 min, at which most of the VLP had been cleared (97%), and 
a second phase, a virtual plateau.
statistics
The following method was used for the recovery time experiments. 
VLP concentration was log10-transformed, and all analyses were 
run on the transformed values. A random-effects linear regres-
sion model where log10-transformed VLP concentration was the 
dependent variable while group (study versus control mice), 
recovery period (1.5, 3, 6, 12, and 24 h), test time [0, 1, 5, 10, 20 
(or 15), and 30 min], and all two-way interactions were included 
in the model as independent categorical variables. Random-
effects regression was used due to the longitudinal nature of the 
observations where the outcomes (log10 VPL concentration) were 
nested within specific mice over time. Additionally, this method 
uses all of the results from all of the mice used in the study. After 
running the random-effects linear regression model, linear con-
trast statements were used to estimate differences between study 
and control mice for specific test times and recovery periods of 
interest. In addition to these differences, the 95% confidence 
interval of the differences and the p-Values are also produced by 
the linear contrast statements. All analyses were run using Stata 
14.1, StataCorp LP, College Station, TX, USA.
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